Fig. 7

TMSB10 promotes GBM MES transformation and facilitates macrophage infiltration. A The mRNA or protein expression level of TMSB10 in different subtypes of GBM. B Correlation between TMSB10 and suppressive immunomodulators. The color indicates the correlation coefficient. GSEA showing the C MES signature and D CORDENONSI_YAP_CONSERVED_SIGNATURE in the high TMSB10 expression group in the TCGA GBM cohort. E Western blot assays showing the protein expression of CD44, YAP1, LOX, as well as phosphorylation levels of AKT and ERK1/2 in GSCs transfected with sh-NC or sh-TMSB10 and ov-NC or ov-TMSB10 as indicated. F (Top) Representative Transwell migration assays showing the chemotaxis capacity of human THP-1-differentiated macrophages by exposing them to CM from GSCs transfected with sh-NC or sh-TMSB10 and ov-NC or ov-TMSB10 as indicated. (Bottom) Quantification histogram representing relative cell numbers; n = 3, scale bar, 100 μm. G Representative flow cytometry histogram showing the proportion of CD163 + in THP-1 differentiated macrophages treated with CM from GSCs transfected with G sh-NC or sh-TMSB10 and H ov-NC or ov-TMSB10 as indicated. The quantification histogram represents the proportion of CD163 + differentiated THP-1 macrophages; n = 3. I Western blot assays showing the protein expression of SPP1 in THP-1 differentiated macrophages treated with CM from GSCs transfected with sh-NC or sh-TMSB10 and ov-NC or ov-TMSB10 as indicated. J Representative IF staining in a human glioma tissue microarray showed that the expression of SPP1 and CD68 was higher in the TMSB10-high group than in the TMSB10-low group. Histogram representing statistical proportion data of positive area. All data are presented as the mean ± SD. The statistical significance is shown as *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001